Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at ASH

Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at ASH 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 11/07/13 --  Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical
data on its investigational hypoxia-targeted drug, TH-302, will be
presented at the 55th Annual Meeting of the American Society of
Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The
presentations will report early data from two ongoing clinical
trials, one evaluating TH-302 as single-agent monotherapy in patients
with advanced leukemias (Abstract #3920), and another evaluating
TH-302 with low-dose dexamethasone in patients with
relapsed/refractory multiple myeloma (Abstract #1948).  
Abstract Details 
Abstract #1948: Phase 1 Study of TH-302, an Investigational
Hypoxia-Targeted Drug, and Dexamethasone in Patients with
Relapsed/Refractory Multiple Myeloma; 5:30 PM - 7:30 PM Central Time
on Saturday, December 7, 2013, in Hall G.  
Abstract #3920: A Phase 1 Study of TH-302, an Investigational
Hypoxia-Targeted Drug, In Patients With Advanced Leukemias; 6:00 PM -
8:00 PM Central Time on Monday, December 9, 2013, in Hall E. 
Abstracts are now available on the ASH website at www.hematology.org. 
About TH-302 
TH-302 is an investigational hypoxia-targeted drug that is designed
to be activated under tumor hypoxic conditions, a hallmark of many
cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due
to insufficient blood supply as a result of aberrant vasculature.
Similarly, the bone marrow of patients with hematological
malignancies has also been shown, in some cases, to be severely
hypoxic. 
TH-302 is currently under evaluation in two Phase 3 trials: one in
combination with doxorubicin versus doxorubicin alone in patients
with soft tissue sarcoma, and the other in combination with
gemcitabine versus gemcitabine and placebo in patients with advanced
pancreatic cancer (MAESTRO). Both Phase 3 trials are being conducted
under Special Protocol Agreements with the U.S. Food and Drug
Administration (FDA). The FDA and the European Commission have
granted TH-302 Orphan Drug Designation for the treatment of soft
tissue sarcoma and pancreatic cancer. TH-302 is also being
investigated in hematological malignancies and in combination with
other therapies in a variety of solid tumors. 
Threshold has a global license and co-development agreement for
TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option
for Threshold to co-commercialize in the U.S. 
About Threshold Pharmaceuticals  
Threshold Pharmaceuticals, Inc. is a biotechnology company focused on
the discovery and development of drugs targeting Tumor Hypoxia, the
low oxygen condition found in microenvironments of most solid tumors
as well as the bone marrows of some hematologic malignancies. This
approach offers broad potential to treat a variety of cancers. By
selectively targeting tumor cells, we are building a pipeline of
drugs that hold promise to be more effective and less toxic to
healthy tissues than conventional anticancer drugs. For additional
information, please visit our website (www.thresholdpharm.com). 
Forward-Looking Statements 
Except for statements of historical fact, the statements in this
press release are forward-looking statements, including statements
regarding the potential use of TH-302 to treat patients with advanced
leukemias or multiple myeloma, other clinical trials of TH-302 and
the therapeutic uses and benefits of TH-302. These statements involve
risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, Threshold's
ability to enroll or complete its anticipated clinical trials, the
time and expense required to conduct such clinical trials and analyze
data, issues arising in the regulatory or manufacturing process and
the results of such clinical trials (including product safety issues
and efficacy results). Further information regarding these and other
risks is included under the heading "Risk Factors" in Threshold's
Quarterly Report on Form 10-Q, which has been filed with the
Securities and Exchange Commission on November 4, 2013 and is
available from the SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We undertake
no duty to update any forward-looking statement made in this news
release. 
Contact  
Laura Hansen, Ph.D.
Senior Director, Corporate Communications
Threshold Pharmaceuticals
Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com